Carolina Liquid Chemistries and Diazyme Enter Into Partnership
By LabMedica International staff writers Posted on 24 Jan 2023 |
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.
In comparison to using time-consuming and labor-intensive immunoassay platforms, it is more economical to run tests on clinical chemistry analyzers. The DZ-Lite c270 is an advanced benchtop clinical chemistry analyzer with a menu of FDA-cleared, moderately complex, and innovative assays made for clinical laboratories of all sizes. The compact clinical chemistry analyzer supports 1, 2, 3, and 4-part reagent assays and has a throughput of up to 270 tests per hour. The analyzer can be used in all types of clinical laboratory settings such as reference laboratories, hospitals, and physician offices with clinical labs.
Related Links:
Carolina Liquid Chemistries, Corp.
Diazyme Laboratories, Inc.
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus